Lundbeck Completes DEEp SEA Randomization; Phase III Bexicaserin Trial In Dravet Syndrome Advances

India, Sept. 15 -- Correction: Changed the company stock symbol from 926.HK to HLUN-B.CO in the stock quote.

H. Lundbeck A/S (HLUNb.CO,HLUKF.OB) announced that the last patient has been randomized in DEEp SEA, its global Phase III trial evaluating investigational bexicaserin in children and adults with Dravet syndrome.

Dravet syndrome is a rare, severe childhood-onset epilepsy classified as a developmental and epileptic encephalopathy (DEE).

The condition is associated with treatment-resistant seizures and significant developmental challenges.

Bexicaserin is an investigational oral, highly selective 5-HT2C receptor superagonist being developed to reduce seizures associated with DEEs.

The therapy is designed to increase inhibitory and d...